Total tumor/edema ratio was predictive of non MGMT promotor methylation from DeepBraTumIA (AUC 0.711, 95% CI 0.582–0.840, sensitivity 44.4%, specificity 92.0%, at Youden optimal cutoff 0.625) and Raidionics (AUC 0.698, 95% CI 0.566–0.829, sensitivity 44.4%, specificity 88.0%, at Youden optimal cutoff 0.638). The gene discussed is MGMT; the disease is neoplasm.